These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28495074)

  • 1. The Rationale for GesEPOC in Our Environment.
    Arnedillo Muñoz A
    Arch Bronconeumol; 2017 Jun; 53(6):293-294. PubMed ID: 28495074
    [No Abstract]   [Full Text] [Related]  

  • 2. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Riesco JA; Trigueros JA; Piñera P; Simón A; López-Campos JL; Soriano JB; Ancochea J;
    Arch Bronconeumol; 2012 Jul; 48(7):247-57. PubMed ID: 22561012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between GesEPOC and GOLD in 2017.
    de-Torres JP; Marin JM
    Arch Bronconeumol; 2017 Jun; 53(6):295-296. PubMed ID: 28506625
    [No Abstract]   [Full Text] [Related]  

  • 4. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Trigueros JA; Cosío BG; Casanova C; Antonio Riesco J; Simonet P; Rigau D; Soriano JB; Ancochea J
    Arch Bronconeumol; 2017 Jun; 53(6):324-335. PubMed ID: 28477954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE guidelines for chronic obstructive pulmonary disease: implications for primary care.
    Gruffydd-Jones K; Jones MM
    Br J Gen Pract; 2011 Feb; 61(583):91-2. PubMed ID: 21276335
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (Gesepoc): The Epoconsul Study.
    Calle Rubio M; Rodríguez Hermosa JL; Soler-Cataluña JJ; López-Campos JL; Alcazar Navarrete B; Soriano JB; Rodríguez Gónzalez-Moro JM; Fuentes Ferrer ME; Miravitlles M;
    Arch Bronconeumol (Engl Ed); 2018 May; 54(5):270-279. PubMed ID: 29361320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Riesco JA; Trigueros JA; Piñera P; Simón A; López-Campos JL; Soriano JB; Ancochea J
    Aten Primaria; 2012 Jul; 44(7):425-37. PubMed ID: 22704760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GOLD in 2017: A View From the Spanish COPD Guidelines (GesCOPD).
    Miravitlles M; Soler-Cataluña JJ
    Arch Bronconeumol; 2017 Mar; 53(3):89-90. PubMed ID: 28159169
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological approaches to stable chronic obstructive pulmonary disease.
    Booker R
    Br J Nurs; 2004 Oct 28-Nov 10; 13(19):1130-4. PubMed ID: 15573005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance in treatment of chronic obstructive pulmonary disease following GesEPOC guideline vs. GOLD.
    Figueira Gonçalves JM; Golpe R; Esteban C; Acosta-Sorensen M; Veiga I; Guzmán-Peralta I
    Rev Clin Esp (Barc); 2021 Nov; 221(9):536-539. PubMed ID: 34518150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UPLIFTing care for chronic obstructive pulmonary disease.
    Davies L; Calverley PM
    Lancet; 2009 Oct; 374(9696):1129-30. PubMed ID: 19716599
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017.
    Erro Iribarren M; Alonso Pérez T; Soriano JB; Ancochea Bermúdez J
    Arch Bronconeumol (Engl Ed); 2020 Mar; 56(3):183-185. PubMed ID: 31722829
    [No Abstract]   [Full Text] [Related]  

  • 13. [Early diagnosis, Uplift and COPD in stage II].
    Mihălţan F; Ulmeanu R
    Pneumologia; 2009; 58(4):263-5. PubMed ID: 20067063
    [No Abstract]   [Full Text] [Related]  

  • 14. [Differences between guidelines on management of COPD].
    Gawlewicz-Mroczka A; Nizankowska-Mogilnicka E
    Pneumonol Alergol Pol; 2006; 74(2):139-43. PubMed ID: 17269359
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is it possible to modify the course of chronic obstructive pulmonary disease with modern medication?].
    Avdeev SN
    Ter Arkh; 2008; 80(8):80-6. PubMed ID: 18807549
    [No Abstract]   [Full Text] [Related]  

  • 16. Classification of the Severity of COPD Exacerbations in Hospitalized Patients According to Rome vs GesEPOC Criteria.
    Amado Diago CA; Figueira Gonçalves JM; Golpe R; Esteban C; Garcia Talavera I; García-Martín S
    Arch Bronconeumol; 2023 Jan; 59(1):57-58. PubMed ID: 35872093
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Treatment in Chronic Obstructive Pulmonary Disease According to GesEPOC 2021 vs. GesEPOC 2017. Approaching Criteria with GOLD 2021?
    Figueira Gonçalves JM; Golpe R; Esteban C; Amado Diago C; García Talavera I; Ramos Izquierdo C
    Arch Bronconeumol; 2022 Apr; 58(4):364-366. PubMed ID: 35312579
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical inquiries: When are antibiotics indicated for acute COPD exacerbations?
    Balser E; Neher JO; Safranek S; Taraday J
    J Fam Pract; 2006 Dec; 55(12):1079-80. PubMed ID: 17137546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease.
    Antoniu SA
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):155-62. PubMed ID: 20384562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.